A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

NCT06182592 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

High-risk (Secondary) Acute Myeloid Leukemia

Interventions

DRUG: Liposomal cytarabine-daunorubicin for injection
DRUG: 7+3 (cytarabine and daunorubicin)

Sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.